Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression : Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies .

 

... Results: 

In total, 123 patients received Trilaciclib and 119 patients received placebo. 

Myeloprotective benefits of Trilaciclib were observed regardless of age, with greater effects observed among patients aged ≥ 65 years. 

Across FN risk factors and categories, Trilaciclib had beneficial effects on neutrophil-related endpoints vs placebo, with greater effects observed in patients at higher risk of FN.

 Effects on RBC-related endpoints favored Trilaciclib vs placebo, regardless of anemia risk factors and categories. 

Improvements in PROs with Trilaciclib were observed irrespective of age group, but with greater improvements and less deterioration from baseline observed in older patients.

Conclusion :

 By both decreasing the incidence of CIM and improving quality of life, Trilaciclib has the potential to allow patients receiving Chemotherapy for ES-SCLC, including patients who are older or more vulnerable to CIM, to receive chemotherapy on schedule and at standard-of-care doses, and to improve the experience for patients receiving Chemotherapy to treat ES-SCLC . ...